BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1016 related articles for article (PubMed ID: 28230908)

  • 1. Probiotics for people with hepatic encephalopathy.
    Dalal R; McGee RG; Riordan SM; Webster AC
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD008716. PubMed ID: 28230908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Probiotics for patients with hepatic encephalopathy.
    McGee RG; Bakens A; Wiley K; Riordan SM; Webster AC
    Cochrane Database Syst Rev; 2011 Nov; (11):CD008716. PubMed ID: 22071855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis.
    Zacharias HD; Zacharias AP; Gluud LL; Morgan MY
    Cochrane Database Syst Rev; 2019 Jun; 6(6):CD012334. PubMed ID: 31204790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis.
    Goh ET; Stokes CS; Sidhu SS; Vilstrup H; Gluud LL; Morgan MY
    Cochrane Database Syst Rev; 2018 May; 5(5):CD012410. PubMed ID: 29762873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.
    Gluud LL; Vilstrup H; Morgan MY
    Cochrane Database Syst Rev; 2016 Apr; 4():CD003044. PubMed ID: 27089005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acetyl-L-carnitine for patients with hepatic encephalopathy.
    Martí-Carvajal AJ; Gluud C; Arevalo-Rodriguez I; Martí-Amarista CE
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD011451. PubMed ID: 30610762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.
    Gluud LL; Vilstrup H; Morgan MY
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD003044. PubMed ID: 27153247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Branched-chain amino acids for people with hepatic encephalopathy.
    Gluud LL; Dam G; Les I; Marchesini G; Borre M; Aagaard NK; Vilstrup H
    Cochrane Database Syst Rev; 2017 May; 5(5):CD001939. PubMed ID: 28518283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Branched-chain amino acids for people with hepatic encephalopathy.
    Gluud LL; Dam G; Les I; Córdoba J; Marchesini G; Borre M; Aagaard NK; Vilstrup H
    Cochrane Database Syst Rev; 2015 Feb; (2):CD001939. PubMed ID: 25715177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Branched-chain amino acids for people with hepatic encephalopathy.
    Gluud LL; Dam G; Les I; Córdoba J; Marchesini G; Borre M; Aagaard NK; Vilstrup H
    Cochrane Database Syst Rev; 2015 Sep; (9):CD001939. PubMed ID: 26377410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis.
    Zacharias HD; Kamel F; Tan J; Kimer N; Gluud LL; Morgan MY
    Cochrane Database Syst Rev; 2023 Jul; 7(7):CD011585. PubMed ID: 37467180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy.
    Goh ET; Andersen ML; Morgan MY; Gluud LL
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD002798. PubMed ID: 28745801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy.
    Goh ET; Andersen ML; Morgan MY; Gluud LL
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD002798. PubMed ID: 28796283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vitamin D supplementation for chronic liver diseases in adults.
    Bjelakovic G; Nikolova D; Bjelakovic M; Gluud C
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011564. PubMed ID: 29099543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Probiotics for treating eczema.
    Makrgeorgou A; Leonardi-Bee J; Bath-Hextall FJ; Murrell DF; Tang ML; Roberts A; Boyle RJ
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD006135. PubMed ID: 30480774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Portosystemic shunts versus endoscopic intervention with or without medical treatment for prevention of rebleeding in people with cirrhosis.
    Simonetti RG; Perricone G; Robbins HL; Battula NR; Weickert MO; Sutton R; Khan S
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD000553. PubMed ID: 33089892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ursodeoxycholic acid for primary biliary cirrhosis.
    Rudic JS; Poropat G; Krstic MN; Bjelakovic G; Gluud C
    Cochrane Database Syst Rev; 2012 Dec; 12(12):CD000551. PubMed ID: 23235576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Probiotics for induction of remission in ulcerative colitis.
    Kaur L; Gordon M; Baines PA; Iheozor-Ejiofor Z; Sinopoulou V; Akobeng AK
    Cochrane Database Syst Rev; 2020 Mar; 3(3):CD005573. PubMed ID: 32128795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nitazoxanide for chronic hepatitis C.
    Nikolova K; Gluud C; Grevstad B; Jakobsen JC
    Cochrane Database Syst Rev; 2014 Apr; 2014(4):CD009182. PubMed ID: 24706397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Probiotics for maintenance of remission in ulcerative colitis.
    Iheozor-Ejiofor Z; Kaur L; Gordon M; Baines PA; Sinopoulou V; Akobeng AK
    Cochrane Database Syst Rev; 2020 Mar; 3(3):CD007443. PubMed ID: 32128794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.